{"id":"W4281385697","doi":"10.1182/blood.2021015014","title":"Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; University of Calgary","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Servier; BeiGene; Adaptive Biotechnologies; TG Therapeutics; Incyte; F. Hoffmann-La Roche; Amsterdam University Medical Centers; Gilead Sciences; Universiteit van Amsterdam; Leukemia and Lymphoma Society; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Amgen; Breast Cancer Research Foundation; Celgene; Pharmacyclics; Genentech; California Institute for Regenerative Medicine","keywords":"Rituximab; Medicine; Venetoclax; Bendamustine; Internal medicine; Regimen; Population; Progression-free survival; Oncology; Chemotherapy regimen; Gastroenterology; Chemotherapy; Surgery; Chronic lymphocytic leukemia; Leukemia; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003496589,0.0001508487,0.0003114985,0.0002283206,0.0001093329,0.00002607458,0.0001032757,0.00008100756,0.0006839983],"category_scores_gemma":[0.0001122414,0.0001461158,0.00005073591,0.0003124973,0.00005011896,0.00009187213,0.0002583512,0.0004596076,0.00003453734],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005076632,"about_ca_system_score_gemma":0.001984617,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004923367,"about_ca_topic_score_gemma":0.0001489959,"domain_scores_codex":[0.9983429,0.0001073782,0.0003192991,0.0003589601,0.0004763233,0.0003950877],"domain_scores_gemma":[0.9993273,0.0001003257,0.0000590136,0.0003654294,0.00003147225,0.0001164438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01055033,0.0185289,0.7814404,0.002390367,0.001984256,0.01840313,0.01079927,0.0008401895,0.1312255,0.0004906111,0.003621469,0.01972558],"study_design_scores_gemma":[0.4649101,0.003381255,0.4127929,0.0003735021,0.0007562676,0.00281589,0.002687863,0.01582547,0.06270841,0.0005987551,0.03154936,0.001600279],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971219,0.001020082,0.000003157488,0.0002081697,0.00009506032,0.0004824678,0.00001493806,0.00006592569,0.0009882393],"genre_scores_gemma":[0.9971553,0.00003854093,0.0001580149,0.0002000986,0.00005862866,0.0002087168,0.00003796991,0.00003618737,0.002106526],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4543597,"threshold_uncertainty_score":0.9987427,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01165059563415755,"score_gpt":0.260368235767024,"score_spread":0.2487176401328665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}